Individualized L-dopa therapy in patients with Parkinson's disease
| Project/Area Number |
24590176
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
MATSUBARA Kazuo 京都大学, 医学(系)研究科(研究院), 教授 (20127533)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YONEZAWA Atsushi 京都大学, 医学研究科, 講師 (90452341)
FUKUDO Masahide 京都大学, 医学研究科, 助教 (60437233)
OMURA Tomohiro 京都大学, 医学研究科, 助教 (00439035)
NAKAGAWA Shunsaku 京都大学, 医学研究科, その他 (50721916)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | パーキンソン病 / L-dopa / ウエアリング・オフ / COMT遺伝子多型 / エンタカポン / L-ドパ / 薬学 / 薬物動態 / 遺伝子多型 / トランスポータ |
|---|
| Outline of Final Research Achievements |
L-dopa remains the gold standard for treating Parkinson's disease (PD); however, long-term L-dopa treatment is associated with motor adverse effects, particularly wearing-off. Entacapone prevents catechol-O-methyltransferase (COMT) from metabolizing L-dopa into 3-methoxy-4-hydroxy-L-phenylalanine in the periphery and ameliorates wearing-off in patients with PD treated with L-dopa for a prolonged period. In the present study, we examined whether the blood concentration of L-dopa was affected by COMT gene polymorphisms in patients taking L-dopa concomitantly with entacapone.
We demonstrated that entacapone did not change the area under the blood concentration-time curve of L-dopa in PD patient who had a low-activity COMT gene. This result suggests that the blood concentration of L-dopa taken concomitantly with entacapone is affected by the COMT gene polymorphism.
|
Report
(4 results)
Research Products
(11 results)
-
-
-
-
-
[Journal Article] Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.2012
Author(s)
Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K.
-
Journal Title
Neurosci Lett
Volume: 521
Issue: 1
Pages: 15-19
DOI
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
